These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1036 related articles for article (PubMed ID: 27440710)
1. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis. Tan W; Sun J; Zhou L; Li Y; Wu X J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148 [TBL] [Abstract][Full Text] [Related]
3. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis. Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256 [TBL] [Abstract][Full Text] [Related]
4. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062 [TBL] [Abstract][Full Text] [Related]
5. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357 [TBL] [Abstract][Full Text] [Related]
7. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440 [TBL] [Abstract][Full Text] [Related]
8. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689 [TBL] [Abstract][Full Text] [Related]
9. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Hadji P; Gamerdinger D; Spieler W; Kann PH; Loeffler H; Articus K; Möricke R; Ziller V Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459 [TBL] [Abstract][Full Text] [Related]
10. Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate. Al-Bogami MM; Alkhorayef MA; Bystrom J; Akanle OA; Al-Adhoubi NK; Jawad AS; Mageed RA Saudi Med J; 2015 Nov; 36(11):1305-11. PubMed ID: 26593163 [TBL] [Abstract][Full Text] [Related]
11. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study. Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638 [TBL] [Abstract][Full Text] [Related]
12. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study. Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496 [TBL] [Abstract][Full Text] [Related]
13. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial. Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426 [TBL] [Abstract][Full Text] [Related]
15. Bone Loss After Denosumab: Only Partial Protection with Zoledronate. Reid IR; Horne AM; Mihov B; Gamble GD Calcif Tissue Int; 2017 Oct; 101(4):371-374. PubMed ID: 28500448 [TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293 [TBL] [Abstract][Full Text] [Related]
17. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ; J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis. Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654 [TBL] [Abstract][Full Text] [Related]
19. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial. Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303 [TBL] [Abstract][Full Text] [Related]
20. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]